舒肝宁注射液治疗急慢性病毒性肝炎患者的疗效观察及安全性分析  

Curative Effect Observation and Safety Analysis of Shuganning Injection in Treatment of Patients with Acute and Chronic Viral Hepatitis

作　　者：单正旺 SHAN Zhengwang(Pharmacy Department,Jianhu County People's Hospital,Yancheng,Jiangsu 224700)

机构地区：[1]建湖县人民医院药学部,江苏盐城224700

出　　处：《智慧健康》2023年第9期65-69,共5页Smart Healthcare

摘　　要：目的探讨分析舒肝宁注射液治疗急慢性病毒性肝炎患者的临床疗效及安全性。方法回顾性分析建湖县人民医院诊治的60例急慢性病毒性肝炎患者,诊治时间为2020年1月-2021年12月,按照治疗方案不同将患者随机分入对照组(n=29)和研究组(n=31)。对照组采取西医方案治疗,研究组采取西医结合舒肝宁注射液方案治疗,对两组患者治疗效果、症状积分、肝功能指标与药品不良反应进行评定。结果研究组总有效率显著高于对照组,差异有统计学意义(P<0.05);治疗14d两组腹胀、乏力、纳差、肝区痛积分均较治疗前显著降低,且与对照组比较,研究腹胀、乏力、纳差、肝区痛积分更低,差异有统计学意义(P<0.05);治疗14d两组ALT、AST、TBil水平均较治疗前显著降低,且相较于对照组,研究组ALT、AST、TBil水平更低,差异有统计学意义(P<0.05);研究组药品不良反应发生率低于对照组,差异无统计学意义(P>0.05)。结论对急慢性病毒性肝炎患者在给予西医治疗基础上加用舒肝宁注射液,总有效率显著提高,患者肝功能显著改善,且未增加药品不良反应,用药安全性高。Objective To explore and analyze clinical effect and safety of Shuganning injection in treatment of patients with acute and chronic viral hepatitis.Methods The paper reviewed and collected 60 patients with acute and chronic viral hepatitis treated in Jianhu County People's Hospital from January 2020 to December 2021,and divided them into control group(n=29)and study group(n=31)according to different treatment schemes randomly.Control group was treated with Western medicine scheme,while research group with combination of Western medicine and Shuganning injection scheme.Treatment effect,symptom scores,liver function indicators and adverse drug reactions were evaluated between of two groups.Results Total effective rate of study group was 93.55%,significantly higher than 68.97%of control group,with statistically significant difference(P<0.05).After 14 days of treatment,scores of abdominal distension,fatigue,anorexia,and liver pain in both groups were significantly lower than before treatment.Scores of abdominal distension,fatigue,anorexia and liver pain in study group were lower than control group,difference was statistically significant(P<0.05).After 14 days of treatment,levels of ALT,AST and TBil in both groups were significantly lower than before treatment,levels of ALT,AST,and TBil in study group were lower than control group,with statistically significant difference(P<0.05).Incidence of adverse drug reactions in study group was 6.45%(2/31),while that in control group was 13.79%(4/29).There was no statistically significant difference between the groups(P>0.05).Conclusion Shuganning injection and Western medicine can significantly improve overall effective rate and liver function for acute and chronic viral hepatitis patients,with no increase adverse drug reactions and safe medication.

关 键 词：舒肝宁注射液 急慢性病毒性肝炎 肝功能 不良反应 

分 类 号：R512.6[医药卫生—内科学]